당뇨병성 궤양 치료 시장 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of diabetic ulcer treatment Market

The global diabetic ulcer treatment market size was valued at USD 5.98 billion in 2025 and is projected to reach USD 6.42 billion in 2026 and USD 11.36 billion by 2034. The market is driven by the increasing prevalence of diabetes, rising incidence of diabetic foot ulcers, growing adoption of advanced wound care products, and continuous advancements in ulcer treatment technologies. North America held the leading position in 2025, supported by advanced healthcare infrastructure, strong research and development activities, and widespread adoption of innovative wound care solutions.

Market Definition and Scope

Diabetic ulcer treatment includes medical products and therapies designed to manage and heal ulcers associated with diabetes, particularly diabetic foot and mouth ulcers. Treatment options include wound-care dressings, wound-care devices, active therapies, skin substitutes, growth factors, sealants, and other advanced solutions. Increasing awareness regarding early diagnosis and treatment is encouraging healthcare providers to adopt specialized ulcer management products.

Market Dynamics

Driver - Increasing Prevalence of Diabetes and Diabetic Ulcers

The rising global diabetic population is creating a larger patient pool requiring ulcer management. Diabetic foot ulcers are particularly challenging to heal and can lead to serious complications when untreated. Increasing hospitalization rates and demand for specialized wound care are therefore supporting market growth.

Trends - Growing Adoption of Advanced Wound Care Devices

Technological advancements are improving diabetic ulcer treatment through innovative wound-care devices and advanced dressing materials. Research into biomaterials such as collagen, chitosan, and skin substitutes is also expanding treatment possibilities. Strategic investments and partnerships are helping companies introduce more effective solutions.

Restraint - High Cost and Limited Awareness

The high cost associated with long-term ulcer management can limit treatment adoption, particularly in low-resource countries. A shortage of trained professionals and limited awareness regarding available treatment options also remain important barriers.

Opportunity - Development of Innovative Therapies

Advances in active therapies, wound-care devices, smart monitoring solutions, and advanced dressings are creating significant market opportunities. Expansion of product availability into emerging economies can further support market growth.

Impact of COVID-19

The pandemic disrupted routine healthcare services and reduced non-emergency hospital visits, affecting the diagnosis and management of chronic wounds. However, the continued need for diabetic ulcer treatment and increasing interest in home-based wound care supported demand for products that could be used outside traditional hospital settings.

Segmentation Analysis

By Ulcer Type

The diabetic foot ulcer segment accounted for the largest market position and is expected to maintain its dominance. Increasing incidences of diabetic foot ulcers, neuropathic conditions, ischemic ulcers, and neuro-ischemic ulcers are supporting demand. Mouth ulcers represent a smaller segment, although growing research into diabetes-related oral complications is creating new treatment opportunities.

By Treatment Type

The wound-care dressings segment is anticipated to dominate the market. Increasing adoption of advanced dressings and ongoing development of innovative materials are strengthening segment growth. Wound-care devices are also expected to expand rapidly due to technologies such as extracorporeal shock wave therapy. Active therapies, including skin grafts, substitutes, growth factors, and sealants, are gaining importance in complex wound management.

By End User

Hospitals are expected to maintain a leading position because of increasing hospitalization rates, specialized wound-care services, and improving healthcare infrastructure. Meanwhile, home-care settings are anticipated to witness strong growth as the geriatric population increases and patients increasingly seek convenient ulcer-management solutions.

Regional Insights

North America

North America dominated the diabetic ulcer treatment market with a 40.87% share in 2025. Strong healthcare infrastructure, technological capabilities, research activities, and adoption of advanced wound-care products support regional growth. The North American market was valued at USD 3.40 billion in 2019.

Europe

Europe is expected to maintain the second position, supported by innovative product launches, established healthcare systems, and increasing adoption of advanced ulcer treatment technologies.

Asia Pacific

Asia Pacific is anticipated to record the highest growth rate. Rising diabetes prevalence, expanding healthcare infrastructure, economic development, and increasing awareness of advanced wound-care therapies are creating substantial opportunities.

Latin America and Middle East & Africa

These regions are expected to experience moderate growth due to increasing unmet healthcare needs and demand for cost-effective diabetic foot ulcer treatment options.

Competitive Landscape

Major companies operating in the diabetic ulcer treatment market include Coloplast Corp, Smith & Nephew, ConvaTec Group Plc, Molnlycke Health Care AB, 3M, Integra LifeSciences Corporation, Cardinal Health, Tissue Regenix, and B. Braun Melsungen AG. Companies are focusing on acquisitions, partnerships, innovative products, and expanded sales channels to strengthen their market positions.

Investment Analysis and Opportunities

Investment opportunities are emerging in advanced wound dressings, remote monitoring, skin substitutes, regenerative therapies, and wound-care devices. Companies expanding into developing markets can benefit from increasing diabetes prevalence and unmet treatment requirements.

New Product Development

New product development is centered on advanced dressings, therapeutic devices, smart monitoring technologies, and biomaterial-based wound-healing solutions. The development of chitosan-based products and remote patient-monitoring technologies demonstrates the industry's shift toward more effective and preventive diabetic ulcer management.

Five Recent Developments

• December 2019: Orpyx Medical Technologies launched Orpyx SI Sensory Insoles with remote patient monitoring for preventing diabetic foot ulcers and neuropathy-related ulcers.
• December 2017: SANUWAVE Health received FDA approval for marketing the Dermapace System for diabetic foot ulcers.
• July 2018: Molnlycke Health Care acquired SastoMed GmbH to expand its chronic wound-care portfolio.
• April 2019: RLS Global received CE marking approval for ChloraSolv, targeting diabetic foot ulcers.
• May 2019: NEO Tech and Podimetrics announced a manufacturing partnership focused on diabetic foot ulcer treatment solutions.

Future Outlook

The market is expected to benefit from the growing diabetic population, increasing awareness of early ulcer management, improved wound-care infrastructure, and continued development of advanced therapies. Digital monitoring, innovative dressings, regenerative medicine, and home-care treatment solutions are likely to become increasingly important through 2034.

Report Coverage

The report provides qualitative and quantitative analysis of the diabetic ulcer treatment industry, including market size, market value, segmentation, regional performance, market trends, growth drivers, restraints, opportunities, competitive landscape, regulatory developments, product pipelines, and key industry developments. The report also evaluates treatment options and emerging technologies across major countries and regions.

Conclusion

The diabetic ulcer treatment market is positioned for sustained expansion from USD 5.98 billion in 2025 to USD 6.42 billion in 2026 and USD 11.36 billion by 2034. Increasing diabetes prevalence, growing adoption of advanced wound-care dressings and devices, and technological innovation will remain major contributors to market development. North America is expected to retain its leadership, while Asia Pacific offers significant growth opportunities due to its expanding diabetic population and improving healthcare infrastructure.

Units Value (USD Billion)

Segmentation By Ulcer Type

• Foot Ulcer
  • Neuropathic Ulcer
  • Ischemic Ulcers
  • Neuro-Ischemic Ulcer
• Mouth Ulcer
• Others

By Treatment Type

• Wound-care Dressings
  • Antimicrobial Dressing
  • Foam Dressings,
  • Film Dressings
  • Alginate Dressings
  • Hydrogel Dressings
  • Other Dressings
• Wound Care Devices
  • Negative Pressure Wound Therapy (NPWT)
  • Ultrasound Therapy
  • Hyperbaric Oxygen Therapy (HBOT)
  • Others
• Active Therapies
  • Skin Grafts & Substitutes
  • Growth Factors
  • Others
• Others

By End User

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Homecare Settings

By Geography

• North America (U.S. and Canada)
• Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
• Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia- Pacific)
• Latin America (Brazil, Mexico, and Rest of Latin America)
• Middle East& Africa (South Africa, GCC and Rest of Middle East & Africa)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Overview of Diabetic Ulcers By Key Country/Sub-region
• 4.2. Novel & Upcoming Innovative Treatment Options for Diabetic Ulcers
• 4.3. The Regulatory and Reimbursement Scenario By Country/Sub-region
• 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, New Product Launches, etc.)
• 4.5. Impact of COVID-19 on Diabetic Ulcers Market

5. Global Diabetic Ulcer Treatment Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Ulcer Type
  • 5.2.1. Foot Ulcer
    • 5.2.1.1. Neuropathic Ulcer
    • 5.2.1.2. Ischemic Ulcer
    • 5.2.1.3. Neuro-ischemic Ulcer
  • 5.2.2. Mouth Ulcer
  • 5.2.3. Others
• 5.3. Market Analysis, Insights and Forecast - By Treatment Type
  • 5.3.1. Wound-care Dressings
    • 5.3.1.1. Antimicrobial Dressing
    • 5.3.1.2. Foam Dressings
    • 5.3.1.3. Film Dressings
    • 5.3.1.4. Alginate Dressings
    • 5.3.1.5. Hydrogel Dressings
    • 5.3.1.6. Other Dressings
  • 5.3.2. Wound Care Devices
    • 5.3.2.1. Negative Pressure Wound Therapy (NPWT)
    • 5.3.2.2. Ultrasound Therapy
    • 5.3.2.3. Hyperbaric Oxygen Therapy (HBOT)
    • 5.3.2.4. Others
  • 5.3.3. Active Therapies
    • 5.3.3.1. Skin Grafts & Substitutes
    • 5.3.3.2. Growth Factors
    • 5.3.3.3. Others
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - By End User
  • 5.4.1. Hospitals
  • 5.4.2. Clinics
  • 5.4.3. Ambulatory Surgical Centers
  • 5.4.4. Homecare Settings
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Diabetic Ulcer Treatment Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis - By Ulcer Type
  • 6.2.1. Foot Ulcer
    • 6.2.1.1. Neuropathic Ulcer
    • 6.2.1.2. Ischemic Ulcer
    • 6.2.1.3. Neuro-ischemic Ulcer
  • 6.2.2. Mouth Ulcer
  • 6.2.3. Others
• 6.3. Market Analysis - By Treatment Type
  • 6.3.1. Wound-care Dressings
    • 6.3.1.1. Antimicrobial Dressing
    • 6.3.1.2. Foam Dressings
    • 6.3.1.3. Film Dressings
    • 6.3.1.4. Alginate Dressings
    • 6.3.1.5. Hydrogel Dressings
    • 6.3.1.6. Other Dressings
  • 6.3.2. Wound Care Devices
    • 6.3.2.1. Negative Pressure Wound Therapy (NPWT)
    • 6.3.2.2. Ultrasound Therapy
    • 6.3.2.3. Hyperbaric Oxygen Therapy (HBOT)
    • 6.3.2.4. Others
  • 6.3.3. Active Therapies
    • 6.3.3.1. Skin Grafts & Substitutes
    • 6.3.3.2. Growth Factors
    • 6.3.3.3. Others
  • 6.3.4. Others
• 6.4. Market Analysis - By End User
  • 6.4.1. Hospitals
  • 6.4.2. Clinics
  • 6.4.3. Ambulatory Surgical Centers
  • 6.4.4. Homecare Settings
• 6.5. Market Analysis - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Diabetic Ulcer Treatment Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis - By Ulcer Type
  • 7.2.1. Foot Ulcer
  • 7.2.2. Neuropathic Ulcer
  • 7.2.3. Ischemic Ulcer
  • 7.2.4. Neuro-ischemic Ulcer
  • 7.2.5. Mouth Ulcer
  • 7.2.6. Others
• 7.3. Market Analysis - By Treatment Type
  • 7.3.1. Wound-care Dressings
    • 7.3.1.1. Antimicrobial Dressing
    • 7.3.1.2. Foam Dressings
    • 7.3.1.3. Film Dressings
    • 7.3.1.4. Alginate Dressings
    • 7.3.1.5. Hydrogel Dressings
    • 7.3.1.6. Other Dressings
  • 7.3.2. Wound Care Devices
    • 7.3.2.1. Negative Pressure Wound Therapy (NPWT)
    • 7.3.2.2. Ultrasound Therapy
    • 7.3.2.3. Hyperbaric Oxygen Therapy (HBOT)
    • 7.3.2.4. Others
  • 7.3.3. Active Therapies
    • 7.3.3.1. Skin Grafts & Substitutes
    • 7.3.3.2. Growth Factors
    • 7.3.3.3. Others
  • 7.3.4. Others
• 7.4. Market Analysis - By End User
  • 7.4.1. Hospitals
  • 7.4.2. Clinics
  • 7.4.3. Ambulatory Surgical Centers
  • 7.4.4. Homecare Settings
• 7.5. Market Analysis - By Country/Sub-region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Diabetic Ulcer Treatment Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis - By Ulcer Type
  • 8.2.1. Foot Ulcer
    • 8.2.1.1. Neuropathic Ulcer
    • 8.2.1.2. Ischemic Ulcer
    • 8.2.1.3. Neuro-ischemic Ulcer
  • 8.2.2. Mouth Ulcer
  • 8.2.3. Others
• 8.3. Market Analysis - By Treatment Type
  • 8.3.1. Wound-care Dressings
    • 8.3.1.1. Antimicrobial Dressing
    • 8.3.1.2. Foam Dressings
    • 8.3.1.3. Film Dressings
    • 8.3.1.4. Alginate Dressings
    • 8.3.1.5. Hydrogel Dressings
    • 8.3.1.6. Other Dressings
  • 8.3.2. Wound Care Devices
    • 8.3.2.1. Negative Pressure Wound Therapy (NPWT)
    • 8.3.2.2. Ultrasound Therapy
    • 8.3.2.3. Hyperbaric Oxygen Therapy (HBOT)
    • 8.3.2.4. Others
  • 8.3.3. Active Therapies
    • 8.3.3.1. Skin Grafts & Substitutes
    • 8.3.3.2. Growth Factors
    • 8.3.3.3. Others
  • 8.3.4. Others
• 8.4. Market Analysis - By End User
  • 8.4.1. Hospitals
  • 8.4.2. Clinics
  • 8.4.3. Ambulatory Surgical Centers
  • 8.4.4. Homecare Settings
• 8.5. Market Analysis - By Country/Sub-region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Diabetic Ulcer Treatment Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis - By Ulcer Type
  • 9.2.1. Foot Ulcer
    • 9.2.1.1. Neuropathic Ulcer
    • 9.2.1.2. Ischemic Ulcer
    • 9.2.1.3. Neuro-ischemic Ulcer
  • 9.2.2. Mouth Ulcer
  • 9.2.3. Others
• 9.3. Market Analysis - By Treatment Type
  • 9.3.1. Wound-care Dressings
    • 9.3.1.1. Antimicrobial Dressing
    • 9.3.1.2. Foam Dressings
    • 9.3.1.3. Film Dressings
    • 9.3.1.4. Alginate Dressings
    • 9.3.1.5. Hydrogel Dressings
    • 9.3.1.6. Other Dressings
  • 9.3.2. Wound Care Devices
    • 9.3.2.1. Negative Pressure Wound Therapy (NPWT)
    • 9.3.2.2. Ultrasound Therapy
    • 9.3.2.3. Hyperbaric Oxygen Therapy (HBOT)
    • 9.3.2.4. Others
  • 9.3.3. Active Therapies
    • 9.3.3.1. Skin Grafts & Substitutes
    • 9.3.3.2. Growth Factors
    • 9.3.3.3. Others
  • 9.3.4. Others
• 9.4. Market Analysis - By End User
  • 9.4.1. Hospitals
  • 9.4.2. Clinics
  • 9.4.3. Ambulatory Surgical Centers
  • 9.4.4. Homecare Settings
• 9.5. Market Analysis - By Country/Sub-region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Diabetic Ulcer Treatment Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Key Findings / Summary
• 10.2. Market Analysis - By Ulcer Type
  • 10.2.1. Foot Ulcer
    • 10.2.1.1. Neuropathic Ulcer
    • 10.2.1.2. Ischemic Ulcer
    • 10.2.1.3. Neuro-ischemic Ulcer
  • 10.2.2. Mouth Ulcer
  • 10.2.3. Others
• 10.3. Market Analysis - By Treatment Type
  • 10.3.1. Wound-care Dressings
    • 10.3.1.1. Antimicrobial Dressing
    • 10.3.1.2. Foam Dressings
    • 10.3.1.3. Film Dressings
    • 10.3.1.4. Alginate Dressings
    • 10.3.1.5. Hydrogel Dressings
    • 10.3.1.6. Other Dressings
  • 10.3.2. Wound Care Devices
    • 10.3.2.1. Negative Pressure Wound Therapy (NPWT)
    • 10.3.2.2. Ultrasound Therapy
    • 10.3.2.3. Hyperbaric Oxygen Therapy (HBOT)
    • 10.3.2.4. Others
  • 10.3.3. Active Therapies
    • 10.3.3.1. Skin Grafts & Substitutes
    • 10.3.3.2. Growth Factors
    • 10.3.3.3. Others
  • 10.3.4. Others
• 10.4. Market Analysis - By End User
  • 10.4.1. Hospitals
  • 10.4.2. Clinics
  • 10.4.3. Ambulatory Surgical Centers
  • 10.4.4. Homecare Settings
• 10.5. Market Analysis - By Country/Sub-region
  • 10.5.1. GCC Countries
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Key Industry Developments
• 11.2. Global Market Share Analysis (2021)
• 11.3. Competition Dashboard
• 11.4. Comparative Analysis - Major Players
• 11.5. Company Profiles
  • 11.5.1. Coloplast Corp
    • 11.5.1.1. Overview,
    • 11.5.1.2. Products & services,
    • 11.5.1.3. SWOT analysis,
    • 11.5.1.4. Recent developments,
    • 11.5.1.5. strategies,
    • 11.5.1.6. financials (based on availability)
  • 11.5.2. Smith & Nephew
    • 11.5.2.1. Overview,
    • 11.5.2.2. Products & services,
    • 11.5.2.3. SWOT analysis,
    • 11.5.2.4. Recent developments,
    • 11.5.2.5. strategies,
    • 11.5.2.6. financials (based on availability)
  • 11.5.3. ConvaTec Group Plc
    • 11.5.3.1. Overview,
    • 11.5.3.2. Products & services,
    • 11.5.3.3. SWOT analysis,
    • 11.5.3.4. Recent developments,
    • 11.5.3.5. strategies,
    • 11.5.3.6. financials (based on availability)
  • 11.5.4. Molnlycke Health Care AB.
    • 11.5.4.1. Overview,
    • 11.5.4.2. Products & services,
    • 11.5.4.3. SWOT analysis,
    • 11.5.4.4. Recent developments,
    • 11.5.4.5. strategies,
    • 11.5.4.6. financials (based on availability)
  • 11.5.5. 3M
    • 11.5.5.1. Overview,
    • 11.5.5.2. Products & services,
    • 11.5.5.3. SWOT analysis,
    • 11.5.5.4. Recent developments,
    • 11.5.5.5. strategies,
    • 11.5.5.6. financials (based on availability)
  • 11.5.6. Integra LifeSciences Corporation.
    • 11.5.6.1. Overview,
    • 11.5.6.2. Products & services,
    • 11.5.6.3. SWOT analysis,
    • 11.5.6.4. Recent developments,
    • 11.5.6.5. strategies,
    • 11.5.6.6. financials (based on availability)
  • 11.5.7. Cardinal Health.
    • 11.5.7.1. Overview,
    • 11.5.7.2. Products & services,
    • 11.5.7.3. SWOT analysis,
    • 11.5.7.4. Recent developments,
    • 11.5.7.5. strategies,
    • 11.5.7.6. financials (based on availability)
  • 11.5.8. Tissue Regenix
    • 11.5.8.1. Overview,
    • 11.5.8.2. Products & services,
    • 11.5.8.3. SWOT analysis,
    • 11.5.8.4. Recent developments,
    • 11.5.8.5. strategies,
    • 11.5.8.6. financials (based on availability)
  • 11.5.9. B. Braun Melsungen AG
    • 11.5.9.1. Overview,
    • 11.5.9.2. Products & services,
    • 11.5.9.3. SWOT analysis,
    • 11.5.9.4. Recent developments,
    • 11.5.9.5. strategies,
    • 11.5.9.6. financials (based on availability)
  • 11.5.10. Other Players
    • 11.5.10.1. Overview,
    • 11.5.10.2. Products & services,
    • 11.5.10.3. SWOT analysis,
    • 11.5.10.4. Recent developments,
    • 11.5.10.5. strategies,
    • 11.5.10.6. financials (based on availability)

12. Strategic Recommendations